Summit Therapeutics plc
(‘Summit' or the 'Company')
Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
Oxford, UK, and Cambridge, MA, US, 7 November 2018 – Summit Therapeutics plc SMMTSUMM)), a leader in new mechanism antibiotic innovation, announces that management will conduct one-on-one meetings at the Jefferies 2018 London Healthcare Conference, taking place 14-15 November 2018 in London, UK. There will be no podium presentation.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.
Contacts
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking | ||
| Panmure Gordon (Joint Broker) | Tel: | +44 (0)20 7886 2500 |
| Freddy Crossley, Corporate Finance James Stearns, Corporate Broking | ||
| MSL Group (US) | Tel: | +1 781 684 6557 |
| Jon Siegal | summit@mslgroup.com | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Jessica Hodgson / | summit@consilium-comms.com | |
| Lindsey Neville |
-END-
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
